HDAC3 and ovarian carcinoma: Studies have demonstrated that HDAC3 inhibition can enhance the efficacy of PARP inhibitors in breast and ovarian cancers by disrupting DNA repair mechanisms, rendering cancer cells more vulnerable to DNA damage [36].